Menu
Back to User profile » Dr Giovanni Bader
Papers published by Dr Giovanni Bader:
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1325-1337
Published Date: 4 May 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:907-922
Published Date: 17 March 2017
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
Vogelmeier C, Zhong NS, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:3189-3197
Published Date: 14 December 2016
Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study
Saab C, Al-Saber FA, Haddad J, Jallo MK, Steitieh H, Bader G, Ibrahim M
Vascular Health and Risk Management 2015, 11:149-155
Published Date: 24 February 2015
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes
Blüher M, Schweizer A, Bader G, Foley JE
Vascular Health and Risk Management 2014, 10:661-664
Published Date: 20 November 2014